Dr. Cheng on Tumor Heterogeneity in HCC and Challenges for Clinical Trials
September 15th 2018Ann-Lii Cheng, MD, PhD, distinguished professor and director of the cancer center of National Taiwan University, discusses the challenges that tumor heterogeneity in hepatocellular carcinoma (HCC) pose for clinical trials.
Read More